Heiden, AMAG’s chief executive officer, will present at the
time. The presentation will include a company overview and business
A live webcast of the presentation will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until June 1, 2013.
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303